A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

Journal of Patient-Reported Outcomes

Table 3 Mean Change in FACT-EGFRI by Patient-Reported Change in Severity and Impact of Skin Symptoms

	FACT EGFRI Total Score
Assessment time	A lot better		A little bit better		About the same		A little bit worse		A lot worse		Mean Diff-erence^a
Assessment time	Mean	N	Mean	N	Mean	N	Mean	N	Mean	N
Change in SEVERITY of skin symptoms
Day 8			−0.50	4	0.86	69	−6.36	33	−17.53	11
Day 15	4.50	2	−1.71	12	0.15	45	−6.96	47	−14.56	16
Day 22	4.43	14	3.98	18	− 0.18	50	−3.67	36	−1.33	3
Day 29	5.76	20	3.00	23	0.21	55	−2.03	21	−2.5	2
Day 36	4.01	16	2.49	28	−0.31	48	0.53	22	−8	1
Day 43	2.20	17	0.64	19	0.04	54	−4.52	21	−7.25	4
Mean	4.17		1.32		0.13		−3.84		−8.53		3.18
Change in IMPACT of skin symptoms on daily life
Day 8			−1.33	3	0.05	84	−9.17	23	−20.5	6
Day 15	4.5	2	−0.4	10	−1.8	66	−8.73	36	−17.13	8
Day 22	3.36	14	8.44	9	−0.75	79	−4.91	17	4	2
Day 29	7.43	14	2.86	21	0.44	70	−2.57	14	−5	2
Day 36	4.22	16	2.19	18	0.42	70	−1.2	11
Day 43	1.91	18	1.23	13	−0.7	71	−5.1	10	−7.33	3
mean	4.28		2.17		−0.39		−5.28		−9.19		3.37

^aUnweighted mean difference calculated as the average of the difference between adjacent levels of patient-reported change categories. For instance, for severity, the difference is calculated as: mean of [4.17–1.32,1.32–0.13, 0.13-(−3.84), −3.84-(−8.53)]